Production (Stage)
Century Therapeutics, Inc.
IPSC
$0.583
$0.00761.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2,515.96% | 427.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2,515.96% | 427.56% | |||
| Cost of Revenue | -9.51% | 7.89% | |||
| Gross Profit | 427.69% | 4.67% | |||
| SG&A Expenses | -7.72% | 9.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.09% | 8.17% | |||
| Operating Income | 316.17% | 1.37% | |||
| Income Before Tax | 323.23% | -9.81% | |||
| Income Tax Expenses | -- | 22,300.00% | |||
| Earnings from Continuing Operations | 312.24% | -15.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 312.24% | -15.52% | |||
| EBIT | 316.17% | 1.37% | |||
| EBITDA | 349.71% | 1.58% | |||
| EPS Basic | 310.75% | -14.57% | |||
| Normalized Basic EPS | 342.71% | 0.56% | |||
| EPS Diluted | 310.75% | -14.57% | |||
| Normalized Diluted EPS | 342.50% | 0.56% | |||
| Average Basic Shares Outstanding | 0.71% | 0.84% | |||
| Average Diluted Shares Outstanding | 0.80% | 0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||